Lemmon Co.'s injectable diazepam labeling
Executive Summary
Company said that validation work on its labeling process for diazepam syringes will be completed in "the next day or so." FDA is currently conducting a GMP inspection at Lemmon, which follows a recall in June involving 44,470 diazepam syringes. A number of the syringes lacked immediate container labels ("The Pink Sheet" July 3, T&G-17). In December, a recall was initiated for the same reason. According to an Aug. 8 FDA reg letter, Lemmon made corrections to prevent a recurrence of unlabeled syringes after the first recall. However, FDA said that it will not approve drug applications until it is determined through reinspection that "adequate corrective action has been taken".
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.